XML 115 R13.htm IDEA: XBRL DOCUMENT
v3.2.0.727

Goodwill and Other Intangible Assets | 12 Months Ended
--- | ---
Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill, by segment and in total:
(in millions) | Pharmaceutical (1) |  | Medical |  | Total
Balance at June 30, 2013 | $ | 2,094 |  |  | $ | 2,507 |  |  | $ | 4,601 |
Goodwill acquired, net of purchase price adjustments | $ | 68 |  |  | $ | 216 |  |  | $ | 284 |
Foreign currency translation adjustments and other | $ | (4 | ) |  | $ | (3 | ) |  | $ | (7 | )
Balance at June 30, 2014 | $ | 2,158 |  |  | $ | 2,720 |  |  | $ | 4,878 |
Goodwill acquired, net of purchase price adjustments | 41 |  |  | 179 |  |  | 220 |
Foreign currency translation adjustments and other | — |  |  | (28 | ) |  | (28 | )
Balance at June 30, 2015 | $ | 2,199 |  |  | $ | 2,871 |  |  | $ | 5,070 |
(1) | At June 30, 2015, 2014 and 2013 the accumulated goodwill impairment loss was $829 million.
The increase in the Medical segment goodwill during fiscal 2014 was primarily due to the AccessClosure acquisition. Goodwill recognized in connection with this acquisition primarily represents the expected benefits from synergies of integrating this business, the existing workforce of the acquired entity, expected growth from new customers and new products, and improvements to existing technologies. See Note 2 for further discussion of this acquisition. Other Intangible Assets Other intangible assets are amortized over periods ranging from one to twenty years. The following tables summarize other intangible assets by class at June 30:
| 2015
(in millions) | Gross Intangible |  | Accumulated Amortization |  | Net Intangible
Indefinite-life intangibles: |  |  |  |  |
Trademarks and other | $ | 14 |  |  | $ | — |  |  | $ | 14 |
Total indefinite-life intangibles | 14 |  |  | — |  |  | 14 |
Definite-life intangibles: |  |  |  |  |
Customer relationships | 1,103 |  |  | 501 |  |  | 602 |
Trademarks, trade names and patents | 237 |  |  | 91 |  |  | 146 |
Developed technology and other | 320 |  |  | 134 |  |  | 186 |
Total definite-life intangibles | 1,660 |  |  | 726 |  |  | 934 |
Total other intangible assets | $ | 1,674 |  |  | $ | 726 |  |  | $ | 948 |
| 2014
(in millions) | Gross Intangible |  | Accumulated Amortization |  | Net Intangible
Indefinite-life intangibles: |  |  |  |  |
Trademarks and other | $ | 14 |  |  | $ | — |  |  | $ | 14 |
Total indefinite-life intangibles | 14 |  |  | — |  |  | 14 |
Definite-life intangibles: |  |  |  |  |
Customer relationships | 1,043 |  |  | 388 |  |  | 655 |
Trademarks, trade names and patents | 213 |  |  | 69 |  |  | 144 |
Developed technology and other | 258 |  |  | 79 |  |  | 179 |
Total definite-life intangibles | 1,514 |  |  | 536 |  |  | 978 |
Total other intangible assets | $ | 1,528 |  |  | $ | 536 |  |  | $ | 992 |
Total amortization of intangible assets was $191 million, $188 million and $121 million for fiscal 2015, 2014 and 2013, respectively. For acquisitions that have closed on or before June 30, 2015, estimated annual amortization of intangible assets for the remainder of fiscal 2016 through 2020 is as follows: $194 million, $184 million, $136 million, $88 million and $79 million. These estimates do not include amortization of intangibles relating to the Harvard Drug and Cordis acquisitions, which may be significant.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration